Mener Bravo mumlet det i podcasetn fra DNB før jul. 10-15 pax. Hør gjerne gjennom selv, mulig jeg husker feil
Var ikke det Bravo som sa at dersom “sikkerhets Cohort” på tre (3) pasienter får en “feil” i avlesning og må forkaste pasient dataen, at de måtte begynne på nytt?
Derav 3 - 6 pasienter benevning i studie oppsettet?
Feiler pasient nr 3 av ulike årsaker så må de behandle pasient nr 4, 5 og 6.
(Ref nyere podcast med Bravo etter husk)
En fersk aksjonærliste for NANO er tilgjengelig for Insider-medlemmer. Ikke Insider? Les mer og prøv gratis
En fersk aksjonærliste for NANO er tilgjengelig for Insider-medlemmer. Ikke Insider? Les mer og prøv gratis
Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre 
Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.
Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:
- @Savepig (425 likes)
- @Fornybar (338 likes)
- @Nocturne (222 likes)
Resten av topp 10:
-
@Snoeffelen (139 likes)
-
@TheObserver (118 likes)
-
@vegar_beider (105 likes)
-
@ezPappi (102 likes)
-
@JTHP (102 likes)
-
@InVivo (91 likes)
-
@TyrionIV (83 likes)
Gratulerer!
1 Like
En fersk aksjonærliste for NANO er tilgjengelig for Insider-medlemmer. Ikke Insider? Les mer og prøv gratis
En fersk aksjonærliste for NANO er tilgjengelig for Insider-medlemmer. Ikke Insider? Les mer og prøv gratis
En fersk aksjonærliste for NANO er tilgjengelig for Insider-medlemmer. Ikke Insider? Les mer og prøv gratis
Oslo, Norway, 21 February 2020
Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2019 Results Presentation and Webcast
Oslo, Norway, 21 February 2020
Nordic Nanovector ASA (OSE: NANO) announces that it will report its results for the fourth quarter and full year 2019 on Thursday, 27 February 2020. A presentation by Nordic Nanovector’s senior management team will take place at 8:30am CET at:
Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo
Meeting Room: VIPPETANGEN
The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investors & Media
The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2019 from 7:00am CET the same day.
For further information, please contact:
IR enquiries
Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
Media Enquiries
Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 638 9571
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.
Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.
Further information can be found at www.nordicnanovector.com.
This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.
This release was sent by Nordic Nanovector AS
@pdx, sovna TekBot på denne?
1 Like
En fersk aksjonærliste for NANO er tilgjengelig for Insider-medlemmer. Ikke Insider? Les mer og prøv gratis
Bra! Takk for at du strammer opp TekBot:’
Håper den ikke har fått virus…
1 Like
Hva har skjedd med Bravo, noen som vet?
Fra meldingen:
Nordic Nanovector ASA (OSE: NANO) announces that Dr Lars Nieba has been appointed interim Chief Executive Officer with immediate effect. Dr Nieba, who is currently the Company’s Chief Technology Officer, replaces Eduardo Bravo who as of today has left Nordic Nanovector to pursue other career opportunities.
Vel, her er link til transkriptet for Nanos Q4 og årsrapport 2019, fra Yahoo Finance. Føde for mørbanka hjerner. Enjoy!
https://finance.yahoo.com/news/edited-transcript-nano-ol-earnings-160719201.html
7 Likes
And another question is, the other recently was approved was under 100 patients, can Betalutin send application on the same number of patients? For example, on the interim results and LYMRIT? And will you submit a rolling BLA?
Lars Nieba, Nordic Nanovector ASA - Interim CEO & CTO [27]
So the last answer is yes, we will submit a rolling BLA. It’s a very good question. And yes, whoever asked that question, that person is absolutely right. There are other molecules out there like Aliqopa and others who filed with roughly 100 patients. And we have, at that time, when we went to the FDA for discussions, it was there in 2016, when I remember it correctly. We discussed it with the FDA, we promised to have 130 patients. But of course, this is 1 of the questions, which we now need to ask ourselves where we need to go through and to think about if – what I meant was looking through the protocol, what is possible from the strategic side to make all the protocol changes. Absolutely.
Marco Renoldi, Nordic Nanovector ASA - COO [28]
And the data may help us.
Lars Nieba, Nordic Nanovector ASA - Interim CEO & CTO [29]
The data may help us.
7 Likes
Ville hellere se at de fik de åbne sites til at inrullere patienter.
1 Like
And is it realistic to be able to enroll the last 83 patients in the last 10 months of 2020?
Lars Nieba, Nordic Nanovector ASA - Interim CEO & CTO [25]
I wouldn’t take the role, if I would say no. So because it is possible. The only thing what we needed to do is now really looking into it, so as mentioned, also in bigger companies where I had been before. It is not always that easy to run a clinical trial. So sometimes you underestimate the patients where they are located, whatever. There are so many things which are contributing to enrollment. So it is now something where we need to have a look into it. And there are companies out there who are specialized into that which might help us. Whatever we can do. We also need to reach out to our KOLs and other areas. So there are so many things which you can do, and we will try all of these things. And we are looking into it and helping our top recruiting sites to recruit more. All of that we will do. And yes, we also look into the strategy of the trial into the protocol. All of that will be done in the next few weeks to enable us to enroll the final patients until the end of the year. And we are strongly believing that, that is possible.
6 Likes
.And I think we are in a pretty good position. Since we are on track with our interim analysis and of course, if these data are very attractive, we might be approached, no question. So from that point, we are open to partnership.
9 Likes
Er vel det som gjerne er planen nå ja. Karre seg forbi interim og forhåpentligvis søke partner etter godkjent interim. Kanskje Bravo var uenig i dette og valgte å gå?
Full kostnadskontroll nå så det ikke blir emi før interrim så kan det allikevel gå bra dette😀
1 Like